Phosphatidylserine Is the Only Supplement with Both an FDA-Qualified Health Claim for Cognitive Dysfunction and an EFSA-Approved Cognitive Performance Claim — the Crook 1991 Trial Showed 300mg/Day for 12 Weeks Produced a Cognitive Reversal Equivalent to 12 Years of Age-Related Decline, Making It the Strongest Evidence Base for Any Single Nutrient in Age-Associated Memory Impairment, While the Cortisol-Attenuation Effect at 800mg Makes It Uniquely Dual-Purpose for Athletes Under Chronic Training Stress

the evidence that earned the FDA and EFSA claims: CROOK TH, TINKLENBERG J, YESAVAGE J, ET AL. (1991, Neurology): the most cited PS cognitive trial; DESIGN: double-blind, placebo-controlled, multi-center RCT; POPULATION: N=149 adults aged 50–75 meeting criteria for Age-Associated Memory Impairment (AAMI) — a diagnostic category for normal age-related cognitive decline; AAMI requires: documented memory complaints; objective performance below age-adjusted norms on neuropsychological testing; no dementia (MMSE ≥24); INTERVENTION: BC-PS (bovine cortex-derived phosphatidylserine) 100mg three times daily (300mg total) × 12 weeks vs identical placebo; OUTCOME MEASURES: 10-test neuropsychological battery including: name-face recognition test (the most sensitive to normal aging); story recall (verbal memory); digit span; misplaced objects; telephone number recall; RESULTS: INTENTION-TO-TREAT ANALYSIS: PS 300mg: statistically significant improvement on the combined neuropsychological battery vs placebo (p<0.05); SUBGROUP FINDING: patients with the worst baseline performance (poorest memory entering the study) showed the greatest absolute improvement; their post-treatment performance on the name-face and story recall tests was equivalent to people approximately 12 years YOUNGER on the population normative curves — hence the "12-year reversal" headline that made this trial famous; PATIENTS AT MODERATE LEVELS OF DECLINE AT ENTRY: showed modest improvement; PATIENTS AT MILD DECLINE: showed no significant benefit (floor effect — insufficient decline to detect improvement); CRITICAL CAVEAT — BOVINE VS SOYBEAN/SUNFLOWER PS: the Crook 1991 trial used BC-PS (bovine cortex phosphatidylserine), which was withdrawn from the market in the mid-1990s due to BSE (bovine spongiform encephalopathy / mad cow disease) concerns; commercial PS is now almost exclusively soy-derived or sunflower-derived; head-to-head equivalence data for soy/sunflower PS vs BC-PS in humans is LIMITED; Engel 1992 (Psychopharmacology): soy PS showed benefits on cognitive testing in elderly — supporting approximate class equivalence but not direct BC-PS bioequivalence; the FDA's 2003 qualified health claim covers soy-derived PS (not BC-PS); EFSA 2010 opinion: supports a positive relationship between PS consumption and cognitive performance in the elderly; POST-CROOK LITERATURE: Kato-Kataoka 2010 (Journal of Clinical Biochemistry and Nutrition, N=78, soy PS 100–300mg × 6 months): significant improvement in name-face recall and memory capacity; Vakhapova 2010 (N=157, sunflower PS-DHA × 15 weeks): significant improvement in immediate and total learning scores vs placebo

why athletes use 800mg PS and the HPA axis data: MONTELEONE 1990 (European Journal of Clinical Pharmacology): the first RCT to demonstrate PS's cortisol-attenuating effects; DESIGN: double-blind, crossover RCT; POPULATION: N=9 healthy male athletes; INTERVENTION: PS 800mg/day × 10 days before exercise challenge vs placebo; EXERCISE CHALLENGE: 90-minute standardized bicycle ergometer protocol at 70% VO₂max; RESULTS: PS group showed: significantly blunted cortisol response to exercise (area under the curve cortisol × time: PS group AUC significantly lower vs placebo, p<0.05); significantly blunted ACTH response (ACTH = corticotropin, the pituitary hormone that drives cortisol production → the attenuation occurs at the HPA axis, not just the adrenal gland); no significant difference in testosterone, growth hormone, or heart rate between conditions; MONTELEONE 1992 (European Journal of Clinical Pharmacology): follow-up in 9 healthy men; PS 800mg × 10 days; acute resistance exercise challenge (resistance training + concurrent aerobic); cortisol and ACTH significantly attenuated in the PS condition vs placebo; IMPLICATIONS FOR OVERTRAINING: chronic excessive exercise (overreaching/overtraining syndrome) is characterized by HPA axis dysregulation → chronically elevated cortisol → impaired recovery, muscle catabolism, suppressed immune function, mood disturbance; PS 600–800mg/day is used by some sports medicine practitioners to blunt this chronic stress response; BENTON 1999 (Nutritional Neuroscience): PS 300mg × 30 days in healthy young adults: improved mood scores and reduced cortisol response to a cognitive stressor (mental arithmetic under time pressure) — extending the effect beyond exercise stress to psychological stress; MECHANISM: PS may attenuate HPA axis activity by: (1) direct effect on hippocampal glucocorticoid receptors (PS restores hippocampal PS content → improves GR sensitivity → hippocampus exerts greater negative feedback on HPA → less ACTH/cortisol output); (2) reducing brain oxidative stress (cortisol production increases with oxidative stress; PS's antioxidant membrane effects may reduce the trigger); (3) direct effect on hypothalamic CRH (corticotropin-releasing hormone) secretion — proposed but not proven in humans

what changed after BSE and why it matters: BC-PS (BOVINE CORTEX) — THE ORIGINAL: derived from pig or cow brain cortex (the richest natural source of PS); fatty acid profile closely matches human brain PS (high in DHA and EPA); bioavailability: excellent — very similar to endogenous brain PS; WITHDRAWN: BSE (mad cow disease, bovine spongiform encephalopathy) crisis in the mid-1990s (peak in UK 1992–1993; identified as cause of variant CJD in humans) → all bovine brain-derived supplements were pulled from commercial markets; no BSE transmission from PS supplements was ever documented, but the precautionary withdrawal was complete; SOY-DERIVED PS (SHARPPS / SOY PS): extracted from soy lecithin via multi-step processing (phospholipase D enzyme transphosphorylation); fatty acid profile: predominantly linoleic acid (C18:2, omega-6) and palmitic acid — significantly DIFFERENT from brain PS; EFSA (2010) and FDA (2003 qualified claim) are based on soy-derived PS studies; major commercial brands: Sharp-PS (Lipogen), Leci-PS; available in most US/EU supplements; SUNFLOWER-DERIVED PS: extracted from sunflower lecithin; fatty acid profile: oleic acid (C18:1) dominant; GMO-free (sunflower is non-GMO by default vs soy); marketed as preferable for consumers avoiding soy (allergy, GMO concerns); increasingly preferred by premium supplement brands; bioavailability data: Vakhapova 2010 study suggests clinical efficacy equivalent to soy PS; PS-DHA CONJUGATES: some products conjugate PS with DHA (docosahexaenoic acid, the omega-3 critical for brain membranes); rationale: PS and DHA are co-located in brain membranes; DHA is required for optimal neuronal membrane fluidity; some animal studies suggest PS-DHA complexes have superior brain uptake vs PS or DHA alone; clinical human data on PS-DHA superior to PS alone: limited; PS-DPA (docosapentaenoic acid) conjugates also exist; ABSORPTION: PS is fat-soluble → take with food (a meal containing fat significantly improves absorption); peak plasma PS increase occurs 2–3 hours post-dose; tissue (brain) accumulation requires weeks of consistent supplementation; BLINDING CHALLENGE: PS has a faint taste detectable by some participants → mild blinding challenge in trials using PS vs placebo capsules

additional evidence base and population applications: ADHD IN CHILDREN: Hirayama 2014 (European Psychiatry, N=36 children aged 4–14 with ADHD): PS 200mg/day × 2 months; significant improvement in inattention and auditory memory; no effect on hyperactivity; Vaisman 2008 (Nutritional Neuroscience, N=36 children with ADHD): PS-omega3 (PS-DHA/EPA) × 15 weeks; significant improvement in ADHD rating scales and visual sustained attention on TOVA (Test of Variables of Attention); COMBINED PS + OMEGA-3: the rationale for combining PS with omega-3 EPA+DHA is mechanistic: DHA is the primary structural omega-3 in neuronal membranes; PS and DHA are found together in the inner leaflet of neuronal membranes; both are required for normal synaptic membrane fluidity; EPA has anti-inflammatory effects at the neuronal level; omega-3 also upregulates PS synthase enzymes (the enzymes that convert PE to PS in the brain) → more dietary DHA/EPA → more PS synthesized in neurons; CLINICAL TRIAL: Manor 2012 (European Psychiatry, N=157, elderly with memory complaints): PS-omega3 (300mg PS + EPA/DHA) × 15 weeks; significant improvement in memory scores; the subgroup with high baseline omega-3 status (serum DHA ≥3rd quartile) showed no benefit — suggesting PS+omega3 is primarily effective in patients who are deficient in both; PARKINSON'S DISEASE — APOPTOSIS SIGNAL: relevant basic science: in neurodegeneration, neurons externalize PS (flip PS to outer leaflet) → triggers microglial phagocytosis → synaptic stripping and neuron loss; PS supplementation may slow this externalization → reduce the pathological "eat me" signal in degenerating neurons; clinical human evidence in PD: limited (pilot data only); ANXIETY AND MOOD: Baumeister 2008 (Nutritional Neuroscience): 200mg/day PS × 6 weeks: improved mood scores in elderly subjects with depressive affect; proposed mechanism: cortisol attenuation + improved hippocampal GR sensitivity → better stress resilience; SLEEP QUALITY: some evidence (Parker 2011) suggesting PS 300mg/day may improve sleep quality in elderly via cortisol normalization — excessive nocturnal cortisol (common in aging HPA dysregulation) disrupts sleep architecture; PS normalization of nocturnal cortisol → improved sleep continuity